2021-06-21 09:44:04

HWGB'S JV PARTNER, EBI SUBMITTED UPDATING REPORT TO US FDA FOR THE COMPLETION OF COVID-19 VACCINATION STUDY

KUALA LUMPUR, 21 JUNE 2021 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), through its wholly-owned subsidiary HWGB Biotech Sdn Bhd (“HWGB Biotech”), today announced E-MO Biology Inc.’s report on the Stage 2 of Phase 4 Clinical Trial had been successfully submitted to the US Food and Drug Administration (“FDA”). The Stage 2 of the Phase 4 Clinical Trial is the study on the additional 275 subjects assessed in relation to the immune responses for the prevention of COVID-19, following a booster dose of inactivated poliovirus (IPV) vaccine in adults.
 
EBI had received approval from the FDA for the commencement of stage 2 of the Phase 4 Clinical Trial after it completed the first stage of the study. On 23 December 2020, EBI successfully submitted their Interim Report of COVID-19 Vaccine study to the FDA and the study showed that 100% of the Subjects produced an immune response that recognized protein (RdRp) of both poliovirus and SARS-Cov-2 in their blood samples after vaccination.
 
HWGB Biotech’s General Manager (Medical & Pharmaceutical Research), Dr. Yaman Walid Kassab said: “We are pleased to announce that our joint venture partner, EBI has submitted the report on the Stage 2 of the Phase 4 Clinical Trial on the additional 275 subjects to the FDA. We are heading in the right direction towards the breakthrough for COVID-19 vaccination as EBI will be able to further their understanding of the cross-reactivity between SARS-Cov-2 virus and poliovirus”.
  
***

Back